NASDAQ:ESPR Esperion Therapeutics - ESPR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.60 +0.04 (+2.56%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.52▼$1.7450-Day Range$1.46▼$7.1752-Week Range$1.26▼$8.87Volume8.13 million shsAverage Volume7.84 million shsMarket Capitalization$122.51 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Esperion Therapeutics MarketRank™ ForecastAnalyst RatingHold2.22 Rating ScoreUpside/Downside597.9% Upside$11.17 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment-0.06Based on 15 Articles This WeekInsider TradingSelling Shares$125,227 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.34) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector181st out of 1,005 stocksPharmaceutical Preparations Industry75th out of 486 stocks 4.1 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 4 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.17, Esperion Therapeutics has a forecasted upside of 597.9% from its current price of $1.60.Amount of Analyst CoverageEsperion Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ESPR. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 2.2 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Esperion Therapeutics this week, compared to 2 articles on an average week.Search Interest44 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 144% compared to the previous 30 days.MarketBeat Follows16 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 220% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $125,227.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions85.87% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($2.34) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Esperion Therapeutics (NASDAQ:ESPR) StockEsperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.Read More Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesMarch 24, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Esperion (ESPR) and Elevance Health (ELV)March 23, 2023 | finance.yahoo.comEsperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?March 26, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 23, 2023 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 22, 2023 | finance.yahoo.comEsperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 22, 2023 | americanbankingnews.comSheldon L. Koenig Sells 6,999 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) StockMarch 22, 2023 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $11.17 Consensus Target Price from BrokeragesMarch 22, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreased by AnalystMarch 26, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 20, 2023 | finance.yahoo.comEsperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 18, 2023 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Rating Reiterated by HC WainwrightMarch 18, 2023 | investing.comEsperion Therapeutics Inc (ESPR)March 17, 2023 | finance.yahoo.com5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' | Pro RecapMarch 17, 2023 | finance.yahoo.comEsperion (ESPR) Plummets 54% Over Milestone Payment RowMarch 16, 2023 | msn.comB of A Securities Downgrades Esperion Therapeutics (ESPR)March 16, 2023 | markets.businessinsider.comWhy Esperion Therapeutics Stock Is Tanking ThursdayMarch 16, 2023 | msn.comEsperion Tanks after Dispute with Daiichi SankyoMarch 16, 2023 | benzinga.comWhat 11 Analyst Ratings Have To Say About Esperion TherapeuticsMarch 16, 2023 | finance.yahoo.comEsperion’s stock tumbles after disclosing dispute about milestone paymentMarch 16, 2023 | investorplace.comWhy Is Esperion Therapeutics (ESPR) Stock Down 60% Today?March 15, 2023 | benzinga.comPresident and CEO at Esperion Therapeutics Acquires Company Stock Options Worth 445,000 SharesMarch 15, 2023 | benzinga.comChief Commercial Officer at Esperion Therapeutics Acquires Company Stock Options Worth 94,500 SharesMarch 15, 2023 | benzinga.comEsperion Therapeutics General Counsel Awarded $336K Worth of Stock OptionsMarch 10, 2023 | finance.yahoo.comEsperion Therapeutics (ESPR) Down 24% in a Week: Here's WhyMarch 8, 2023 | finance.yahoo.comInternational Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular RiskMarch 7, 2023 | msn.comEsperion upgraded at Credit Suisse despite selloff after Nexletol dataMarch 6, 2023 | msn.comEsperion Therapeutics Stock Is Diving: What's Going On?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Company Calendar Last Earnings2/21/2023Today3/26/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees218Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.17 High Stock Price Forecast$22.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+597.9%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-233,660,000.00 Net Margins-309.58% Pretax Margin-309.58% Return on EquityN/A Return on Assets-77.40% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.29 Sales & Book Value Annual Sales$75.47 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value($4.39) per share Price / Book-0.36Miscellaneous Outstanding Shares76,570,000Free Float74,046,000Market Cap$122.51 million OptionableOptionable Beta0.25 Key ExecutivesSheldon L. KoenigPresident, Chief Executive Officer & DirectorBenjamin HalladayChief Financial OfficerKen FiorelliChief Technical Operations OfficerJoAnne Micale FoodyChief Medical OfficerWilliam J. SasielaSenior Vice President-Clinical DevelopmentKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTDURECTNASDAQ:DRRXVeruNASDAQ:VERUViveon Health AcquisitionNYSE:VHAQPuma BiotechnologyNASDAQ:PBYIView All CompetitorsInsiders & InstitutionsSheldon L KoenigSold 6,999 sharesTotal: $12,458.22 ($1.78/share)Joanne M FoodySold 3,808 sharesTotal: $6,778.24 ($1.78/share)Sheldon L KoenigSold 5,441 sharesTotal: $27,531.46 ($5.06/share)Eric WarrenSold 5,090 sharesTotal: $25,704.50 ($5.05/share)Alliancebernstein L.P.Bought 11,647 shares on 2/16/2023Ownership: 0.074%View All Insider TransactionsView All Institutional Transactions ESPR Stock - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price forecast for 2023? 9 brokers have issued 1 year price targets for Esperion Therapeutics' shares. Their ESPR share price forecasts range from $1.50 to $22.00. On average, they expect the company's share price to reach $11.17 in the next year. This suggests a possible upside of 597.9% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2023? Esperion Therapeutics' stock was trading at $6.23 at the start of the year. Since then, ESPR stock has decreased by 74.3% and is now trading at $1.60. View the best growth stocks for 2023 here. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, February, 21st. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.11. The biopharmaceutical company earned $18.18 million during the quarter, compared to the consensus estimate of $20.60 million. The company's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period last year, the business posted ($1.77) earnings per share. What ETFs hold Esperion Therapeutics' stock? ETFs with the largest weight of Esperion Therapeutics (NASDAQ:ESPR) stock in their portfolio include Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), SPDR S&P Pharmaceuticals ETF (XPH), Principal Healthcare Innovators ETF (BTEC) and ProShares Ultra Nasdaq Biotechnology (BIB) and What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Braidwell LP (4.61%), Two Sigma Investments LP (2.09%), Geode Capital Management LLC (1.74%), ExodusPoint Capital Management LP (1.59%), Norges Bank (1.00%) and Schonfeld Strategic Advisors LLC (0.96%). Insiders that own company stock include Benjamin Looker, Eric Warren, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $1.60. How much money does Esperion Therapeutics make? Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $122.51 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis. How many employees does Esperion Therapeutics have? The company employs 218 workers across the globe. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com. This page (NASDAQ:ESPR) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.